Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation

被引:47
|
作者
Mutis, T
Blokland, E
Kester, M
Schrama, E
Goulmy, E
机构
[1] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2333 ZA Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Hematol, NL-2333 ZA Leiden, Netherlands
关键词
D O I
10.1182/blood-2002-01-0024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Successful stem cell transplantation (SCT) across HLA barriers can be performed with cord blood, megadoses of stem cells, or with nonmyeloablative conditioning strategies. Because the HLA-mismatched transplants are often T-cell depleted, leukemia relapse rates are high. Treatment of relapsed leukemia after HLA-mismatched SCT is difficult. A novel potential strategy to treat relapsed leukemia after HLA-mismatched SCT is the use of patients' mismatched HLA molecules as antigen-presenting molecules to generate hematopoietic system-specific cytotoxic T cells (CTLs) from the stem cell donor. Adoptive transfer of these hematopoetic system-specific CTLs that are restricted by nonself HLA molecules may eliminate leukemia without affecting the patient's nonhematopoietic cells or donor hematopoietic cells. We investigated the feasibility of this strategy using the hematopoletic system-specific minor histocompatibility antigen HA-1, which is known to induce HLA-A2-restricted CTLs. HLA-A2(-) peripheral blood mononuclear cells were stimulated with HLA-A2(+) T2 cells pulsed with synthetic HA-1 peptide or with dendritic cells transduced with the HA-1 cDNA. Tetrameric HLA-A2/HA-1 peptide complexes were used to monitor and enrich HA-1-specific CTLs. In the alloreactive cultures, HA-1-specific CTLs were enriched up to 7% by 3 rounds of antigen-specific stimulations and up to 87% by fluorescence-activated cell sorting of tetramer-positive T cells. The HA-1-specific CTLs showed specific lysis of the relevant target cells, including leukemic cells. Because the polyclonal CTL cultures also contained natural killer cells and allo-HLA-A2-specific CTLs, CTL clones were generated that showed the expected HA-1 specificity only. Thus, HA-1-specific CTLs restricted by nonself HLA-A2 molecules can be generated in an HLA-A2-mismatched setting.
引用
收藏
页码:547 / 552
页数:6
相关论文
共 50 条
  • [21] Minor histocompatibility antigen HA-8 mismatch and clinical outcome after hla-identical sibling donor allogeneic stem cell transplantation
    Perez-Garcia, Arianne
    De la Camara, Rafael
    Torres, Antonio
    Gonzalez, Marcos
    Jimenez, Antonio
    Gallardo, David
    HAEMATOLOGICA, 2005, 90 (12) : 1723 - 1724
  • [22] Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia
    Marijt, WAE
    Heemskerk, MHM
    Kloosterboer, FM
    Goulmy, E
    Kester, MGD
    van der Hoorn, MAWG
    van Luxemburg-Heys, SAP
    Hoogeboom, M
    Mutis, T
    Drijfhout, JW
    van Rood, JJ
    Willemze, R
    Falkenburg, JHF
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (05) : 2742 - 2747
  • [23] Administration of GD2 Chimeric Antigen Receptor Modified, Tri-Virus Specific Cytotoxic T Lymphocytes after HLA Mismatched Allogeneic Stem Cell Transplantation for Relapsed, Refractory Neuroblastoma
    Myers, Doug
    Sun, Jiali
    Rooney, Cliona M.
    Lapteva, Natalia
    Gee, Adrian P.
    Dotti, Gianpietro
    Grilley, Bambi
    Brenner, Malcolm K.
    Ryan, Robin
    MOLECULAR THERAPY, 2013, 21 : S5 - S6
  • [24] Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia
    Huang, Xiao-Jun
    Liu, Dai-Hong
    Liu, Kai-Yan
    Xu, Lan-Ping
    Chen, Yu-Hong
    Wang, Yu
    Han, Wei
    Chen, Huan
    JOURNAL OF CLINICAL IMMUNOLOGY, 2008, 28 (03) : 276 - 283
  • [25] Modified Donor Lymphocyte Infusion after HLA-Mismatched/Haploidentical T Cell-replete Hematopoietic Stem Cell Transplantation for Prophylaxis of Relapse of Leukemia in Patients with Advanced Leukemia
    Xiao-Jun Huang
    Dai-Hong Liu
    Kai-Yan Liu
    Lan-Ping Xu
    Yu-Hong Chen
    Yu Wang
    Wei Han
    Huan Chen
    Journal of Clinical Immunology, 2008, 28 : 276 - 283
  • [26] Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation
    Roy, Denis-Claude
    Delisle, Jean-Sebastien
    Ahmad, Imran
    Leber, Brian
    Couture, Felix
    Thiant, Stephanie
    Kekre, Natasha
    Boumedine, Radia Sidi
    Carli, Cedric
    Brasey, Ann
    Bambace, Nadia M.
    Bernard, Lea
    Cohen, Sandra
    Kiss, Thomas L.
    Roy, Jean
    Sauvageau, Guy
    Veilleux, Olivier
    Perreault, Claude
    Busque, Lambert
    Lachance, Silvy
    BLOOD, 2022, 140 : 1601 - 1603
  • [27] Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation
    Barakat, Carolyne
    Inagaki, Yuichiro
    Mizuno, Shohei
    Nishio, Nobuhiro
    Katsuyama, Naoya
    Sato, Yoshie
    Kobayashi, Miki
    Ozeki, Kazutaka
    Iida, Hiroatsu
    Tomita, Akihiro
    Sawa, Masashi
    Demachi-Okamura, Ayako
    Takahashi, Yoshiyuki
    Nishikawa, Hiroyoshi
    Akatsuka, Yoshiki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (02) : 252 - 266
  • [28] Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation
    Carolyne Barakat
    Yuichiro Inagaki
    Shohei Mizuno
    Nobuhiro Nishio
    Naoya Katsuyama
    Yoshie Sato
    Miki Kobayashi
    Kazutaka Ozeki
    Hiroatsu Iida
    Akihiro Tomita
    Masashi Sawa
    Ayako Demachi-Okamura
    Yoshiyuki Takahashi
    Hiroyoshi Nishikawa
    Yoshiki Akatsuka
    International Journal of Hematology, 2023, 118 : 252 - 266
  • [29] Donor-derived cytomegalovirus-specific CD8+ T cells restricted to shared, donor-specific, or host-specific HLA after HLA mismatched hematopoietic stem cell transplantation
    Ikegame, Kazuhiro
    Fukunaga, Keiko
    Osugi, Yuko
    Kaida, Katsuji
    Teramoto, Masahiro
    Inoue, Takayuki
    Okada, Masaya
    Yoshihara, Kyoko
    Tamaki, Hiroya
    Yoshihara, Satoshi
    Fujiwara, Hiroshi
    TRANSPLANT IMMUNOLOGY, 2024, 87
  • [30] Clinical outcome after Ha-1 minor histocompatibility antigen mismatched stem cell transplantation from Hla-identical sibling donors.: A study from the GVHD subcommittee of the Spanish group for hematopoietic transplantation (GETH).
    Aróstegui, JI
    Balas, A
    Torres, A
    Caballero, D
    Carreras, E
    Brunet, S
    Jimenez, A
    Granena, A
    Mataix, R
    Serrano, D
    Vallejo, C
    Sanz, MA
    Solano, C
    Rodriguez-Luaces, M
    Marin, J
    Baro, J
    Sanz, C
    Román, J
    González, M
    Martorell, J
    Sierra, J
    Martin, C
    de la Cámara, R
    Gallardo, D
    BONE MARROW TRANSPLANTATION, 2001, 27 : S49 - S50